Modulation of the humoral immune response by targeting CD40 and FcγRII/III; delivery of soluble but not particulate antigen to CD40 enhances antibody responses with a Th1 bias

Molecular Immunology

Volumn 49, Issue 1-2, 2011, Pages 155-162

  Szekeres, Zsuzsanna ^b   Herbáth, Melinda ^a   Szittner, Zoltán ^a   Papp, Krisztián ^b   Erdei, Anna ^a,b   Prechl, József ^b  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Antigen; CD40; Fc RII III; Nanoparticles; ScFv; Streptavidin; Targeting

Indexed keywords

CD16 ANTIGEN; CD40 ANTIGEN; FC RECEPTOR; FC RECEPTOR II; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; NANOBEAD; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BIOTINYLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MICROARRAY; TH1 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS; ANTIGENS, CD40; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNITY, HUMORAL; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MICE; MICE, INBRED BALB C; MICROSPHERES; PROTEIN ARRAY ANALYSIS; RECEPTORS, IGG; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STREPTAVIDIN; TH1 CELLS;

MUS;

EID: 82455164099     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.08.008     Document Type: Article

References (35)

1. Angyal A., Szekeres Z., Balogh P., Neer Z., Szarka E., Virag V., Medgyesi D., Prechl J., Sarmay G. CD16/32-specific biotinylated 2.4G2 single-chain Fv complexed with avidin-FITC enhances FITC-specific humoral immune response in vivo in a CD16-dependent manner. Int. Immunol. 2010, 22:71-80.
2. Arpin C., Dechanet J., Van Kooten C., Merville P., Grouard G., Briere F., Banchereau J., Liu Y.J. Generation of memory B cells and plasma cells in vitro. Science 1995, 268:720-722.
3. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10:787-796.
4. Ballantyne J., Henry D.L., Muller J.R., Briere F., Snapper C.M., Kehry M., Marcu K.B. Efficient recombination of a switch substrate retrovector in CD40-activated B lymphocytes: implications for the control of CH gene switch recombination. J. Immunol. 1998, 161:1336-1347.
5. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
6. Barr T.A., Carlring J., Heath A.W. Co-stimulatory agonists as immunological adjuvants. Vaccine 2006, 24:3399-3407.
7. Barr T.A., McCormick A.L., Carlring J., Heath A.W. A potent adjuvant effect of CD40 antibody attached to antigen. Immunology 2003, 109:87-92.
8. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 2002, 196:1627-1638.
9. Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., Offringa R., Toes R.E. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 1999, 5:774-779.
10. Dullforce P., Sutton D.C., Heath A.W. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nat. Med. 1998, 4:88-91.
11. Ferlin W.G., von der Weid T., Cottrez F., Ferrick D.A., Coffman R.L., Howard M.C. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb. Eur. J. Immunol. 1998, 28:525-531.
12. Foy T.M., Aruffo A., Bajorath J., Buhlmann J.E., Noelle R.J. Immune regulation by CD40 and its ligand GP39. Annu. Rev. Immunol. 1996, 14:591-617.
13. French R.R., Taraban V.Y., Crowther G.R., Rowley T.F., Gray J.C., Johnson P.W., Tutt A.L., Al-Shamkhani A., Glennie M.J. Eradication of lymphoma by CD8T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007, 109:4810-4815.
14. Frleta D., Demian D., Wade W.F. Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo. Int. Immunopharmacol. 2001, 1:265-275.
15. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 1998, 16:111-135.
16. Hasbold J., Hong J.S., Kehry M.R., Hodgkin P.D. Integrating signals from IFN-gamma and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a. J. Immunol. 1999, 163:4175-4181.
17. Hasbold J., Johnson-Leger C., Atkins C.J., Clark E.A., Klaus G.G. Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies. Eur. J. Immunol. 1994, 24:1835-1842.
18. Hatzifoti C., Heath A.W. CD40-mediated enhancement of immune responses against three forms of influenza vaccine. Immunology 2007, 122:98-106.
19. Heyman B. Feedback regulation by IgG antibodies. Immunol. Lett. 2003, 88:157-161.
20. Kawabe T., Naka T., Yoshida K., Tanaka T., Fujiwara H., Suematsu S., Yoshida N., Kishimoto T., Kikutani H. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994, 1:167-178.
21. Khanna R., Cooper L., Kienzle N., Moss D.J., Burrows S.R., Khanna K.K. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J. Immunol. 1997, 159:5782-5785.
22. Kim J.J., Simbiri K.A., Sin J.I., Dang K., Oh J., Dentchev T., Lee D., Nottingham L.K., Chalian A.A., McCallus D., Ciccarelli R., Agadjanyan M.G., Weiner D.B. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J. Interferon Cytokine Res. 1999, 19:77-84.
23. Koch F., Stanzl U., Jennewein P., Janke K., Heufler C., Kampgen E., Romani N., Schuler G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 1996, 184:741-746.
24. Mackey M.F., Barth R.J., Noelle R.J. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J. Leukoc. Biol. 1998, 63:418-428.
25. Phan T.G., Green J.A., Gray E.E., Xu Y., Cyster J.G. Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat. Immunol. 2009, 10:786-793.
26. Prechl J., Tchorbanov A., Horvath A., Baiu D.C., Hazenbos W., Rajnavolgyi E., Kurucz I., Capel P.J., Erdei A. Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies. Immunopharmacology 1999, 42:159-165.
27. Qiao S.W., Kobayashi K., Johansen F.E., Sollid L.M., Andersen J.T., Milford E., Roopenian D.C., Lencer W.I., Blumberg R.S. Dependence of antibody-mediated presentation of antigen on FcRn. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9337-9342.
28. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009, 30:23-32.
29. Szekeres Z., Herbath M., Angyal A., Szittner Z., Virag V., Balogh P., Erdei A., Prechl J. Modulation of immune response by combined targeting of complement receptors and low-affinity Fcgamma receptors. Immunol. Lett. 2010, 130:66-73.
30. Toes R.E., Schoenberger S.P., van der Voort E.I., Offringa R., Melief C.J. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin. Immunol. 1998, 10:443-448.
31. Turner J.G., Rakhmilevich A.L., Burdelya L., Neal Z., Imboden M., Sondel P.M., Yu H. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J. Immunol. 2001, 166:89-94.
32. van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
33. Wilson N.S., Yang B., Yang A., Loeser S., Marsters S., Lawrence D., Li Y., Pitti R., Totpal K., Yee S., Ross S., Vernes J.M., Lu Y., Adams C., Offringa R., Kelley B., Hymowitz S., Daniel D., Meng G., Ashkenazi A. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011, 19:101-113.
34. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., Plebanski M. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 2006, 40:1-9.
35. Zhang M., Yao Z., Dubois S., Ju W., Muller J.R., Waldmann T.A. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7513-7518.